Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Analysis of residual perinatal transmission of hepatitis B virus (HBV) and of genetic variants in human immunodeficiency virus and HBV co-infected women and their offspring.

Khamduang W, Gaudy-Graffin C, Ngo-Giang-Huong N, Jourdain G, Moreau A, Borkird T, Layangool P, Kamonpakorn N, Jitphiankha W, Kwanchaipanich R, Potchalongsin S, Lallemant M, Sirirungsi W, Goudeau A; Program for HIV Prevention and Treatment (PHPT) group..

J Clin Virol. 2013 Oct;58(2):415-21. doi: 10.1016/j.jcv.2013.06.025. Epub 2013 Aug 2.

2.

Laboratory and clinical predictors of disease progression following initiation of combination therapy in HIV-infected adults in Thailand.

Duong T, Jourdain G, Ngo-Giang-Huong N, Le Cœur S, Kantipong P, Buranabanjasatean S, Leenasirimakul P, Ariyadej S, Tansuphasawasdikul S, Thongpaen S, Lallemant M; Program for HIV Prevention and Treatment Study Group..

PLoS One. 2012;7(8):e43375. Epub 2012 Aug 15.

3.

Long-term hepatitis B virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand.

Khamduang W, Gaudy-Graffin C, Ngo-Giang-Huong N, Jourdain G, Moreau A, Luekamlung N, Halue G, Buranawanitchakorn Y, Kunkongkapan S, Buranabanjasatean S, Lallemant M, Sirirungsi W, Goudeau A; Program for HIV Prevention and Treatment Study Group..

PLoS One. 2012;7(7):e42184. Epub 2012 Jul 31.

4.

Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand.

Fregonese F, Collins IJ, Jourdain G, Lecoeur S, Cressey TR, Ngo-Giang-Houng N, Banchongkit S, Chutanunta A, Techapornroong M, Lallemant M; Program for HIV Prevention and Treatment Study Group..

J Acquir Immune Defic Syndr. 2012 May 1;60(1):91-8. doi: 10.1097/QAI.0b013e31824bd33f.

PMID:
22293548
5.

The interrelated transmission of HIV-1 and cytomegalovirus during gestation and delivery in the offspring of HIV-infected mothers.

Khamduang W, Jourdain G, Sirirungsi W, Layangool P, Kanjanavanit S, Krittigamas P, Pagdi K, Somsamai R, Sirinontakan S, Hinjiranandana T, Ardonk W, Hongsiriwon S, Nanta S, Borkird T, Lallemant M, McIntosh K, Ngo-Giang-Huong N; Program for HIV Prevention and Treatment (PHPT) Study Group..

J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):188-92. doi: 10.1097/QAI.0b013e31822d0433.

6.

Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy.

Cressey TR, Jourdain G, Rawangban B, Varadisai S, Kongpanichkul R, Sabsanong P, Yuthavisuthi P, Chirayus S, Ngo-Giang-Huong N, Voramongkol N, Pattarakulwanich S, Lallemant M; PHPT-5 Team..

AIDS. 2010 Sep 10;24(14):2193-200. doi: 10.1097/QAD.0b013e32833ce57d.

7.

Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure.

Jourdain G, Wagner TA, Ngo-Giang-Huong N, Sirirungsi W, Klinbuayaem V, Fregonese F, Nantasen I, Techapornroong M, Halue G, Nilmanat A, Wittayapraparat P, Chalermpolprapa V, Pathipvanich P, Yuthavisuthi P, Frenkel LM, Lallemant M; Program for HIV Prevention and Treatment (PHPT) Study Group..

Clin Infect Dis. 2010 May 15;50(10):1397-404. doi: 10.1086/652148.

8.

Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.

Lallemant M, Ngo-Giang-Huong N, Jourdain G, Traisaithit P, Cressey TR, Collins IJ, Jarupanich T, Sukhumanant T, Achalapong J, Sabsanong P, Chotivanich N, Winiyakul N, Ariyadej S, Kanjanasing A, Ratanakosol J, Hemvuttiphan J, Kengsakul K, Wannapira W, Sittipiyasakul V, Pornkitprasarn W, Liampongsabuddhi P, McIntosh K, Van Dyke RB, Frenkel LM, Koetsawang S, Le Coeur S, Kanchana S; PHPT-4 Study Team..

Clin Infect Dis. 2010 Mar 15;50(6):898-908. doi: 10.1086/650745.

Supplemental Content

Loading ...
Support Center